Compare
Puma Biotechnology, Inc. vs Akebia Therapeutics, Inc. vs IDEAYA Biosciences, Inc. vs Vanda Pharmaceuticals Inc.
| Latest fiscal year | Puma Biotechnology, Inc. PBYI | Akebia Therapeutics, Inc. AKBA | IDEAYA Biosciences, Inc. IDYA | Vanda Pharmaceuticals Inc. VNDA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $228.37M | $236.20M | $218.71M | $216.10M |
| Revenue growth (YoY) | -0.9% | +47.5% | n/m | +8.7% |
| Gross margin | 74.5% (computed) | 83.3% (computed) | n/a | n/a |
| Operating margin | 16.3% | 9.9% | -72.8% | -70.0% |
| Net margin | 13.6% | -2.3% | -52.0% | -102.0% |
| Net income | $31.11M | -$5.34M | -$113.70M | -$220.47M |
| EPS (Diluted) | $0.61 | -$0.02 | -$1.28 | -$3.74 |
| Operating cash flow | $41.80M | $67.99M | -$71.10M | -$109.44M |
| Free cash flow | $41.73M | $67.70M | -$73.47M | -$110.44M |
| Cash & equivalents | $29.64M | $184.84M | $112.83M | $84.85M |
| Total assets | $216.30M | $376.56M | $1.11B | $488.95M |
| Total liabilities | $85.96M | $343.95M | $86.39M | $161.76M |
| Shareholders' equity | $130.34M | $32.61M | $1.02B | $327.19M |
| Return on year-end equity | 23.9% | -16.4% | -11.1% | -67.4% |
| Shares outstanding | 50.41M | 265.42M | 87.80M | 59.10M |
Revenue, most recent five fiscal years
| Fiscal year | Puma Biotechnology, Inc. | Akebia Therapeutics, Inc. | IDEAYA Biosciences, Inc. | Vanda Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $228.37M Ended 2025-12-31 | $236.20M Ended 2025-12-31 | $218.71M Ended 2025-12-31 | $216.10M Ended 2025-12-31 |
| 1 year earlier | $230.47M Ended 2024-12-31 | $160.18M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $198.77M Ended 2024-12-31 |
| 2 years earlier | $235.64M Ended 2023-12-31 | $194.62M Ended 2023-12-31 | $23.39M Ended 2023-12-31 | $192.64M Ended 2023-12-31 |
| 3 years earlier | $228.03M Ended 2022-12-31 | $292.48M Ended 2022-12-31 | $50.93M Ended 2022-12-31 | $254.38M Ended 2022-12-31 |
| 4 years earlier | $253.16M Ended 2021-12-31 | $211.65M Ended 2021-12-31 | $27.94M Ended 2021-12-31 | $268.68M Ended 2021-12-31 |